Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02171273 · ClinicalTrials.gov registry record · NA
Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02171273: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT02171273 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02171273, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The overall objectives of the proposed study are to examine the consequences of chronic circadian disruption and chronic sleep restriction on metabolic function in healthy adults.
Primary Outcome
Euglycemic hyperinsulinemic clamp-assessed measure of insulin sensitivity
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Sleep Restriction
- BEHAVIORAL Circadian Disruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-03-31 |
| Est. Completion | 2019-04-01 |
| Phase | NA |
What the finished NCT02171273 record still lists
NCT02171273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Control is the first listed.
NCT02171273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02171273 about?
NCT02171273 is a clinical study titled "Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism". The overall objectives of the proposed study are to examine the consequences of chronic circadian disruption and chronic sleep restriction on metabolic function in healthy adults.
What is the current status of trial NCT02171273?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-03-31. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT02171273?
The interventions under investigation include: Control (BEHAVIORAL), Sleep Restriction (BEHAVIORAL), Circadian Disruption (BEHAVIORAL).
Who is sponsoring clinical trial NCT02171273?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02171273's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI